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Pain and Disability scales were used to quantify pain and disability. Catas-
trophizing was measured with the Pain Catastrophizing Scale. Repeated
measures general linear models were used to compare the patients in the
treatment group to a usual care cohort of 45 patients who also had received
knee arthroplasty and had high pain catastrophizing but no pain coping
skills training. Patient groups has comparable baseline characteristics.
Results: Compared to the usual care cohort, the patients who received pain
coping skills training reported signiﬁcantly greater and clinically important
reductions in pain severity and catastrophizing, and greater improvements
in function, two months after surgery (see table).
Conclusions: The ﬁndings provide preliminary evidence that the pain
coping skills treatment may be highly eﬃcacious for reducing pain, catas-
trophizing, and disability, in patients reporting elevated catastrophizing
prior to knee arthroplasty. A randomized clinical trial is warranted to
conﬁrm these effects.
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Purpose: Knee joint replacement is a successful, effective and cost effective
procedure for the treatment of osteoarthritis (OA). However, there are a
small number of patients who complain of persistent pain in the operated
joint, in spite of an apparently good technical outcome.
This study is a preliminary investigation into the causes of persistent pain
in the operated knee after technically successful medial uni-compartmental
knee joint replacement for antero-medial knee OA.
Methods: People with persistent knee pain of no known cause, and a
duration of 6 months or more after medial compartment UKR for OA,
were invited to attend a special clinic where a full history was taken, and
examination including quantitative sensory testing carried out. 21 subjects
agreed to attend.
Results: 18 of the 21 patients were women (compared with a F:M ratio of
1.1:1 for all UKRs done in the unit), their mean age was 58 (range 43-69)
and the mean interval since operation was 13 months (range 6 months to
3.5 years). Their current pain was described as severe by 10, moderate in
9 and mild in 1 case. 16 of the 21 subjects described the pain as quite
different in quality from the arthritis pain that they had experienced prior
to surgery, and 10 people described transient sharp attacks of spontaneous
pain in addition to their ‘usual’ more constant pain. On the basis of the
history and examination, patients were divided into three overlapping
groups:
1. Neuropathic pain: Sensory testing revealed allodynia in 10 cases, which
was severe in 7 and associated with a high score on ‘PainDetect’ question-
naires.
2. Mechanical pain: This group (n=7) complained of pain which was either
similar to that prior to surgery (5) and/or clearly associated with activity.
Examination suggested that the pain was coming from other compartments
of the knee, (e.g. patello-femoral joint), or from periarticular soft tissues.
3. Infero-medial bone pain: This group of another 7 patients complained of a
new sort of pain developing post-operatively, characterised by a dull ache
radiating down the medial side of the tibia, unrelated to activity.
In 5 cases there appeared to be a mixture of features, including aspects of
two or more of the above categories
Conclusions: Pain in OA joints with technically successful prostheses is
not uncommon and has a number of different causes. In the case of UKR,
a speciﬁc syndrome of antero-medial ‘bone’ pain can develop, in addition
to mechanical or neuropathic pain. These different types of pain can be
distinguished in clinic, and require different therapeutic approaches.
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Purpose: Failure of large interventional, controlled studies in osteoarthritis
(OA) is not uncommon. If a study includes an internal control ("gold stan-
dard"), reasons other than failure of the experimental drug can be explored.
Poor study conduct at investigational sites is one of the reasons why a
study may fail. We explored and exempliﬁed the problem using two large
multicenter phase III studies with similar design and inclusion/exclusion
criteria investigating Diractin® (Ketoprofen Transfersome® Gel). Whereas
Study 1 showed statistically signiﬁcant results on pain, Study 2 failed to
conﬁrm those in the primary data analysis.
Methods: Study 1 was a multi-center, randomized, double-blind, multiple
dose, parallel group, placebo-controlled study investigating three different
dosages of ketoprofen in Diractin® in patients with OA of the knee (100
mg bid [n=223], 50 mg bid [n=223], 25 mg bid [n=221] and placebo
[n=199]) for a treatment period of 12 weeks. Study 2 was a multi-center,
randomized, double-blind, double-dummy, multiple dose, parallel group,
placebo- and active (naproxen)-controlled study investigating Diractin® in
the same dosages (100 mg bid [n = 164], 50 mg bid [n = 172], and 25 mg
bid [n = 175]), naproxen 500 mg bid [n = 164] and placebo [n = 162] for
12 weeks. Both studies used the VAS version of the WOMAC pain subscale
to evaluate effects on pain. Due to the high dropout rate of study 2 and
the weak response of the reference drug, the concept of “quality sites” was
introduced. A “quality site” was deﬁned by: 1) at least one patient per
treatment group received study medication, and 2) less than 50% major
protocol violations observed. The difference in study outcome for “quality”
and “non-quality sites” was evaluated using standard statistical methods
for the comparison of the placebo group to the naproxen group.
Results: In Study 1, 100 mg bid and 50 mg bid of ketoprofen in Diractin®
showed statistically signiﬁcant effects on pain (p = 0.0383 and p = 0.0204,
resp.). However, the primary analysis of Study 2 failed to show a statis-
tically signiﬁcant effect for Diractin®. The following differences between
Study 1 and Study 2 were observed with respect to study conduct.
Table 1. Key conduct features of the clinical studies
# Randomised # Per Protocol Patients Drop-out Screening failure
Patients/Site per Site Rate Rate
Study 1 28.0 21.0 17% 27%
Study 2 9.3 6.1 42% 92%
If the concept of “quality and non-quality sites” was introduced for Study
2, the statistical comparison of naproxen vs. placebo showed p = 0.0005 for
the “quality sites” as compared to p = 0.3679 for the “non-quality sites”.
Conclusions: Study conduct at the investigational site is crucial to detect
therapeutic effects on pain during interventional studies in OA of the knee.
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Purpose: The aim was to study the early progression of pain of patients
with both hip and knee complaints over 2 years. We planned on using three
different models in order to identify factors associated with progression of
pain and to assess what strategy we should use to investigate changes in
complaints due to (early) osteoarthritis.
Methods: A prospective cohort of 1002 participants with complaints of
knee and/or hip was formed between October ‘02 and September ‘05. The
participants will be followed for a period of at least 10 years.
Individuals were eligible to participate in the study if they had pain and/or
stiffness of knee and/or hip, were aged between 45 and 65 years, and
had never of or not longer than 6 months ago visited the GP for these
symptoms for the ﬁrst time. Exclusion criteria were any other pathological
condition that could explain the existing symptoms.
The primary outcome measures of this study were change in the Western
Ontario MacMaster questionnaire (WOMAC) pain subscale from baseline to
two years follow up.
Determinants were factors from the baseline assessment including: de-
mographic factors, factors relating to symptoms, co morbidities and
interventions, measurements from a physical examination, factors relating
to participation and lifestyle, radiographic assessments, and psychological
factors.
A univariate analysis was done on the 47 variables that were deemed
relevant. The variables that were related to the outcome (p<0.20) were
